Skip to main content

Table 2 Feasibility measures

From: Intravenous albumin for the prevention of hemodynamic instability during sustained low-efficiency dialysis: a randomized controlled feasibility trial (The SAFER-SLED Study)

Protocol adherence measurements

Saline (n = 123 sessions)

Albumin (n = 148 sessions)

Overall (n = 271 sessions)

Protocol adherence for both doses*, n (%)

109 (89)

135 (91)

244 (90)

Assigned albumin or placebo not given at start of SLED, n (%)

4 (3)

7 (5)

11 (4)

Assigned albumin or placebo not given after 4 h of SLED, n (%)

10 (8)

6 (4)

16 (6)

Both doses of assigned albumin or placebo not given, n (%)

0 (0)

0 (0)

0 (0)

Contamination measurements

 Received non-study intravenous albumin during the SLED session, n (%)

19 (15)

13 (9)

32 (12)

  1. SLED: sustained low-efficiency dialysis
  2. *Sessions for which patient correctly received both doses of either albumin or placebo
  3. Nine patients (30%) received non-study intravenous albumin during SLED sessions at least once (for 17 sessions it was given as 100 mL of 25% albumin once, in one session it was given twice, and in one session 250 mL of 5% albumin was given once)
  4. Six patients (20%) received non-study intravenous albumin during SLED sessions at least once (for 10 sessions it was given as 100 mL of 25% once, in 2 sessions it was given twice, and in one session 250 mL of 5% albumin was given twice)